GlionAI Biotherapeutics
Computational drug design and molecular-glue therapeutics development.
Health Tech & Life Sciences
Non Active, Jun 2026 ceased to operate
Company Overview
Snapshot
Founded in May 2025, GlionAI Biotherapeutics operates with 1–10 employees. The company is currently in a non-active status, having ceased operations in June 2026.
Business overview
GlionAI Biotherapeutics specializes in developing computational tools for drug design and advancing molecular-glue therapeutics programs. The company focuses on computational drug planning and molecular-glue drug development within the Health Tech & Life Sciences sector, specifically targeting Pharma & Medical Biotechnology and Drugs Discovery & Development.
Company Intelligence Q&A
- What is GlionAI Biotherapeutics' primary focus?
- GlionAI Biotherapeutics focuses on computational drug design and the development of molecular-glue therapeutics programs.
- When was GlionAI Biotherapeutics founded?
- GlionAI Biotherapeutics was founded in May 2025.
- What is the current operational status of GlionAI Biotherapeutics?
- GlionAI Biotherapeutics is currently non-active, having ceased operations in June 2026.
- In which sector does GlionAI Biotherapeutics primarily operate?
- GlionAI Biotherapeutics operates within the Health Tech & Life Sciences sector, with a specific focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- Where is GlionAI Biotherapeutics headquartered?
- GlionAI Biotherapeutics is headquartered in Pardes Hanna-Karkur, Israel.